Avidity Drug Shows Yearlong Gains In Duchenne Muscular Dystrophy Trial
Avidity’s del-zota treatment improved muscle function, increased dystrophin levels, and reduced damage markers in Duchenne muscular dystrophy after one year. read more
Read More
Oracle’s Exceptional Backlog Confirms Its Role As Key AI Enabler: Analyst
Oracle’s shares rose after strong Q1 results driven by cloud and AI growth and record contracts. Analysts see it as a leader in the expanding AI market. Latest Ratings for ORCL Date Firm Action From To Mar 2022 B of A Securities Maintains Neutral Mar 2022 BMO Capital Maintains Market Perform Mar 2022 Piper Sandler…
Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types
PMV Pharma’s Phase 2 trial shows 33% response in TP53 Y220C-mutated tumors, with ovarian cancer achieving a 43% response rate in interim results. read more
BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients
BioXcel’s Phase 3 trial shows BXCL501 effectively reduces agitation in bipolar and schizophrenia patients, supporting its at-home treatment use. read more
FDA Expands Approval For AstraZeneca’s Drug For Pediatric Patients With Rare Type Of Cancer
The FDA approved AstraZeneca’s Koselugo for children 1+ with NF1 and inoperable nerve tumors, expanding treatment options with an established safe dose. read more
Deep Dive Into Acadia Healthcare Co Stock: Analyst Perspectives (7 Ratings)
Latest Ratings for ACHC Date Firm Action From To Mar 2022 Credit Suisse Maintains Outperform Mar 2022 SVB Leerink Maintains Outperform Nov 2021 Credit Suisse Maintains Outperform View More Analyst Ratings for ACHC View the Latest Analyst Ratings read more